Study Findings from State University of New Jersey Provide New Insights into Sodium-Glucose Transporter 2 Inhibitors (Pharmacist-led Review of Empagliflozin and Ertugliflozin Following Formulary Update): Drugs and Therapies – Sodium-Glucose Transporter 2 Inhibitors

2023 SEP 27 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- New research on Drugs and Therapies - Sodium-Glucose Transporter 2 Inhibitors is the subject of a report. According to news originating from Piscataway, New Jersey, by NewsRx correspondents, research stated, “To evaluate the appropriateness of the medication management for anyone who might have been affected by the Horizon New Jersey Health Medicaid Health Maintenance Organization (HNJH Medicaid HMO) formulary update from empagliflozin to ertugliflozin and to then optimize drug selection and monitoring. This is a single-center, 2-phase, pilot project led by 2 pharmacy students and the lead clinical pharmacist at a federally qualified health center in Trenton, New Jersey.”

Financial supporters for this research include Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, Henry J. Austin Health Center.

Our news journalists obtained a quote from the research from the State University of New Jersey, “The primary outcome of the study is the number and percentage of patients whose prescription was changed inappropriately from empagliflozin to ertugliflozin. Secondary outcomes include the number and percentage of patients whose prescription was changed inappropriately because of failure to consider cardiovascular history and/ or missed renal function checks and whether pharmacists were able to optimize therapy. Data were generated from electronic health record reports and analyzed in Microsoft Excel. A total of 126 unique patients were identified as receiving empagliflozin and/or ertugliflozin and 16 patients were switched from empagliflozin to ertugliflozin, all of whom had HNJH Medicaid HMO. Thirteen of the 16 (81.3%) patients were managed inappropriately based on their history of cardiovascular disease or inappropriate renal monitoring. Pharmacists recommended 22 interventions for patients who received empagliflozin and/or ertugliflozin, and all recommendations were accepted by providers.”

According to the news editors, the research concluded: “Following the HNJH Medicaid HMO’s coverage update from empagliflozin to ertugliflozin, some patients received inappropriate therapy and providers accepted clinical pharmacists’ recommendations to optimize therapy.”

This research has been peer-reviewed.

For more information on this research see: Pharmacist-led Review of Empagliflozin and Ertugliflozin Following Formulary Update. The American Journal of Managed Care, 2023;29(8):424-428. The American Journal of Managed Care can be contacted at: Managed Care & Healthcare Communications Llc, 666 Plainsboro Rd, Ste 300, Plainsboro, NJ 08536, USA.

The news correspondents report that additional information may be obtained from M. Thomas Bateman Jr, State University of New Jersey, Ernest Mario School of Pharmacy, Rutgers University - The State University of New Jersey, Piscataway, NJ, United States. Additional authors for this research include Ryan Nguyen, Ashwini B. Navathe and Caitlin Mccarthy.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.37765/ajmc.2023.89408. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)